Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126840 | 0.91 | NFE2L2 (0.43) | NFE2L2MEN1KMT2AACHECYP1A1 | |
| SCHEMBL13126939 | 0.84 | CYP1A1 (0.54) | NFE2L2MEN1KMT2ACYP1A1CYP1B1 | |
| SCHEMBL10069736 | 0.83 | MEN1 (0.41) | NFE2L2MEN1KMT2APOLBCYP1A1 | |
| SCHEMBL10069079 | 0.77 | CYP1A1 (0.53) | NFE2L2MEN1KMT2APOLBACHE | |
| SCHEMBL13127029 | 0.76 | MEN1 (0.37) | NFE2L2MEN1KMT2APOLBACHE | |
| SCHEMBL10069081 | 0.76 | CYP1A2 (0.69) | NFE2L2MEN1KMT2ACYP1A1CYP1B1 | |
| SCHEMBL10069743 | 0.75 | NFE2L2 (0.40) | NFE2L2MEN1KMT2APOLBCYP1A1 | |
| SCHEMBL10069087 | 0.75 | CYP1A1 (0.45) | NFE2L2MEN1KMT2APOLBACHE | |
| SCHEMBL31689790 | 0.74 | NFE2L2 (0.55) | NFE2L2CYP1A1CYP1B1CYP1A2CYP19A1 | |
| SCHEMBL31689795 | 0.74 | NFE2L2 (0.55) | NFE2L2CYP1A1CYP1B1CYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124626-B2 | Methods of treating inflammations and infections with pyridinium salts | MYCOSOL, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7820696-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | KLEIN RICHARD B | 2010-10-21 | — | — | US | disclosed |
| US-7547444-B1 | Methods for controlling fungi and bacteria | MYCOSOL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090137639-A1 | METHODS FOR CONTROLLING FUNGI AND BACTERIA | MYCOSOL, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1601652-B1 | PYRIDINIUM SALTS, COMPOUNDS AND METHODS OF USE | MYCOSOL INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | MYCOSOL, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | BLVRB, PNPO, PLPBP | NFE2L2 3995/4885MEN1 353/4885KMT2A 1264/4885 |
| US-20090137639-A1 | METHODS FOR CONTROLLING FUNGI AND BACTERIA | PNPO, BLVRB, DPM1 | NFE2L2 4495/4885MEN1 808/4885KMT2A 1155/4885 |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | PNPO, PLPBP, TPMT | NFE2L2 1044/4885MEN1 2265/4885KMT2A 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.